Literature DB >> 27581037

Nanomedicine to Overcome Current Parkinson's Treatment Liabilities: A Systematic Review.

Gabriel Henrique Hawthorne1, Marcelo Picinin Bernuci2, Mariza Bortolanza3, Vitor Tumas4, Ana Carolina Issy5, Elaine Del-Bel3.   

Abstract

Nanoparticles might be produced and manipulated to present a large spectrum of properties. The physicochemical features of the engineered nanomaterials confer to them different features, including the ability to cross the blood-brain barrier. The main objective of this review is to present the state-of-art research in nano manipulation concerning Parkinson's disease (PD). In the past few years, the association of drugs with nanoparticles solidly improved treatment outcomes. We systematically reviewed 28 studies, describing their potential contributions regarding the role of nanomedicine to increase the efficacy of known pharmacological strategies for PD treatment. Data from animal models resulted in the (i) improvement of pharmacological properties, (ii) more stable drug concentrations, (iii) longer half-live and (iv) attenuation of pharmacological adverse effects. As this approach is recent, with many of the described works being published less than 5 years ago, the expectancy is that this knowledge gives support to an improvement in the current clinical methods to the management of PD and other neurodegenerative diseases.

Entities:  

Keywords:  Nanomedicine; Nanoparticles; Nanotechnology; Parkinson’s disease

Mesh:

Substances:

Year:  2016        PMID: 27581037     DOI: 10.1007/s12640-016-9663-z

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  88 in total

1.  Formulation and in vitro-in vivo evaluation of piribedil solid lipid micro- and nanoparticles.

Authors:  M Demirel; Y Yazan; R H Müller; F Kiliç; B Bozan
Journal:  J Microencapsul       Date:  2001 May-Jun       Impact factor: 3.142

2.  Activation of DREAM (downstream regulatory element antagonistic modulator), a calcium-binding protein, reduces L-DOPA-induced dyskinesias in mice.

Authors:  Irene Ruiz-DeDiego; Britt Mellstrom; Mario Vallejo; Jose R Naranjo; Rosario Moratalla
Journal:  Biol Psychiatry       Date:  2014-03-27       Impact factor: 13.382

Review 3.  Nanotechnology in glucose monitoring: advances and challenges in the last 10 years.

Authors:  Viviana Scognamiglio
Journal:  Biosens Bioelectron       Date:  2013-03-14       Impact factor: 10.618

Review 4.  The phosphorylation of α-synuclein: development and implication for the mechanism and therapy of the Parkinson's disease.

Authors:  Yan Xu; Yulin Deng; Hong Qing
Journal:  J Neurochem       Date:  2015-08-03       Impact factor: 5.372

5.  Dopaminergic regulation of olfactory type G-protein α subunit expression in the striatum.

Authors:  I Ruiz-DeDiego; J R Naranjo; D Hervé; R Moratalla
Journal:  Mov Disord       Date:  2015-03-15       Impact factor: 10.338

6.  Dopamine-loaded chitosan nanoparticles: formulation and analytical characterization.

Authors:  Elvira De Giglio; Adriana Trapani; Damiana Cafagna; Luigia Sabbatini; Stefania Cometa
Journal:  Anal Bioanal Chem       Date:  2011-04-28       Impact factor: 4.142

7.  Formulation and characterization of intranasal mucoadhesive nanoparticulates and thermo-reversible gel of levodopa for brain delivery.

Authors:  Sumit Sharma; Shikha Lohan; R S R Murthy
Journal:  Drug Dev Ind Pharm       Date:  2013-04-19       Impact factor: 3.225

Review 8.  Comparative efficacy of selegiline versus rasagiline in the treatment of early Parkinson's disease.

Authors:  S Marconi; T Zwingers
Journal:  Eur Rev Med Pharmacol Sci       Date:  2014-07       Impact factor: 3.507

9.  Human dopamine receptor nanovesicles for gate-potential modulators in high-performance field-effect transistor biosensors.

Authors:  Seon Joo Park; Hyun Seok Song; Oh Seok Kwon; Ji Hyun Chung; Seung Hwan Lee; Ji Hyun An; Sae Ryun Ahn; Ji Eun Lee; Hyeonseok Yoon; Tai Hyun Park; Jyongsik Jang
Journal:  Sci Rep       Date:  2014-03-11       Impact factor: 4.379

10.  Magneto-electric nano-particles for non-invasive brain stimulation.

Authors:  Kun Yue; Rakesh Guduru; Jeongmin Hong; Ping Liang; Madhavan Nair; Sakhrat Khizroev
Journal:  PLoS One       Date:  2012-09-05       Impact factor: 3.240

View more
  3 in total

Review 1.  Leveraging the interplay of nanotechnology and neuroscience: Designing new avenues for treating central nervous system disorders.

Authors:  Elizabeth S Smith; Joshua E Porterfield; Rangaramanujam M Kannan
Journal:  Adv Drug Deliv Rev       Date:  2019-03-04       Impact factor: 15.470

Review 2.  Nanogels as Novel Nanocarrier Systems for Efficient Delivery of CNS Therapeutics.

Authors:  Yunhan Zhang; Zhulin Zou; Shuang Liu; Shengjie Miao; Haiyan Liu
Journal:  Front Bioeng Biotechnol       Date:  2022-07-19

3.  Novel Nanoparticles Based on N,O-Carboxymethyl Chitosan-Dopamine Amide Conjugate for Nose-to-Brain Delivery.

Authors:  Adriana Trapani; Stefania Cometa; Elvira De Giglio; Filomena Corbo; Roberta Cassano; Maria Luisa Di Gioia; Sonia Trombino; Md Niamat Hossain; Sante Di Gioia; Giuseppe Trapani; Massimo Conese
Journal:  Pharmaceutics       Date:  2022-01-08       Impact factor: 6.321

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.